The U.K. National Institute for Health and Clinical Excellence issued a draft guidance that would reverse a 2006 decision to restrict patient access to certain Alzheimer's disease drugs. The agency recommended that Eisai and Pfizer's Aricept, Novartis' Exelon and Shire's Reminyl be covered by the National Health Service for patients with mild and moderate Alzheimer's.

Full Story:

Related Summaries